Related Experiment Video
Updated: Jun 26, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Bevacizumab (avastin) for corneal neovascularization--corneal light shield soaked application
Sarah E Mackenzie1, William R Tucker, Tom R G Poole
1Eye Unit, Frimley Park Hospital, Frimley, Camberley, Surrey, UK.
Purpose:
To describe a case where topical bevacizumab (Avastin) was used in an attempt to reduce corneal neovascularization before corneal graft.
Methods:
Topical bevacizumab was applied through a corneal light shield for 20 minutes once a week for 11 weeks to the cornea.
Results:
Corneal vascularization was not reduced.
Conclusions:
Topical bevacizumab was not effective in this case at reducing corneal neovascularization.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems
Diabetic Retinopathy
Glaucoma: Overview
